Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Company profile
Ticker
CSBR
Exchange
Website
CEO
Dr. Ronnie Morris M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
BEXY COMMUNICATIONS INC, CHENIERE ENERGY INC
SEC CIK
Corporate docs
Subsidiaries
Name Incorporated • Champions Oncology UK Limited • Champions Oncology, Israel, Limited • Champions Oncology, SRL • Corellia AI Inc ...
IRS number
521401755
CSBR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-8
Registration of securities for employees
30 Oct 24
8-K
Submission of Matters to a Vote of Security Holders
15 Oct 24
8-K
Departure of Directors or Certain Officers
3 Oct 24
10-Q
2025 Q1
Quarterly report
13 Sep 24
8-K
Champions Oncology Reports Quarterly Revenue of $14.1 Million
11 Sep 24
DEFA14A
Additional proxy soliciting materials
27 Aug 24
DEF 14A
Definitive proxy
27 Aug 24
10-K
2024 FY
Annual report
19 Jul 24
8-K
Champions Oncology Reports Quarterly Revenue of $14.0 Million
18 Jul 24
10-Q
2024 Q3
Quarterly report
14 Mar 24
Transcripts
CSBR
Earnings call transcript
2025 Q1
11 Sep 24
CSBR
Earnings call transcript
2024 Q4
18 Jul 24
CSBR
Earnings call transcript
2024 Q3
12 Mar 24
CSBR
Earnings call transcript
2024 Q2
12 Dec 23
CSBR
Earnings call transcript
2024 Q1
13 Sep 23
CSBR
Earnings call transcript
2024 Q1
13 Sep 23
CSBR
Earnings call transcript
2023 Q4
24 Jul 23
CSBR
Earnings call transcript
2023 Q4
24 Jul 23
CSBR
Earnings call transcript
2023 Q3
15 Mar 23
CSBR
Earnings call transcript
2023 Q2
14 Dec 22
Latest ownership filings
4
JOEL ACKERMAN
1 Nov 24
SC 13D/A
New Enterprise Associates 14, L.P.
6 May 24
4
Brady Davis
1 Apr 24
SC 13G
TOCQUEVILLE ASSET MANAGEMENT L.P.
12 Feb 24
4
Daniel Newman Mendelson
16 Jan 24
4
Daniel Newman Mendelson
12 Jan 24
4
Daniel Newman Mendelson
11 Jan 24
4
Daniel Newman Mendelson
10 Jan 24
4
Daniel Newman Mendelson
9 Jan 24
4
Daniel Newman Mendelson
8 Jan 24
Financial summary
Quarter (USD) | Jul 24 | Apr 24 | Jan 24 | Oct 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Apr 24 | Apr 23 | Apr 22 | Apr 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm | 2.89 mm |
Cash burn (monthly) | (no burn) | 164.75 k | (no burn) | 297.83 k | (no burn) | 149.83 k |
Cash used (since last report) | n/a | 548.09 k | n/a | 990.83 k | n/a | 498.46 k |
Cash remaining | n/a | 2.34 mm | n/a | 1.90 mm | n/a | 2.39 mm |
Runway (months of cash) | n/a | 14.2 | n/a | 6.4 | n/a | 16.0 |
Institutional ownership, Q2 2024
19.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 0 |
Closed positions | 18 |
Increased positions | 2 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.18 bn |
Total shares | 2.66 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 14 | 1.71 mm | $9.37 mm |
West Elk Partners | 676.94 k | $6.40 mm |
Renaissance Technologies | 122.59 k | $633.80 mm |
Geode Capital Management | 63.09 k | $326.24 mm |
Acadian Asset Management | 30.70 k | $157.00 k |
BK The Bank of New York Mellon Corporation | 26.75 k | $138.29 mm |
Cambridge Investment Research Advisors | 12.25 k | $63.00 k |
Mesirow Financial Investment Management | 12.00 k | $62.04 mm |
Simplex Trading | 3.00 k | $15.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Oct 24 | Ackerman Joel | Common Stock | Option exercise | Acquire M | No | No | 5.43 | 16,667 | 90.50 k | 962,134 |
31 Oct 24 | Ackerman Joel | Common Stock | Option exercise | Acquire M | No | No | 2.1 | 88,470 | 185.79 k | 945,467 |
31 Oct 24 | Ackerman Joel | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 5.43 | 16,667 | 90.50 k | 0 |
31 Oct 24 | Ackerman Joel | Option to purchase Common Stock Common Stock | Option exercise | Dispose M | No | No | 2.1 | 88,470 | 185.79 k | 0 |
12 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.5 | 1,000 | 6.50 k | 198,625 |
11 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.27 | 2,000 | 12.54 k | 197,625 |
10 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.31 | 2,944 | 18.58 k | 195,625 |
9 Jan 24 | Mendelson Daniel Newman | Common Stock | Buy | Acquire P | No | No | 6.25 | 3,000 | 18.75 k | 192,681 |
News
Market-Moving News for September 12th
12 Sep 24
Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6
12 Sep 24
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
12 Sep 24
Kroger, Adobe And 3 Stocks To Watch Heading Into Thursday
12 Sep 24
Champions Oncology Q1 Adj $0.11 Beats $(0.03) Estimate, Sales $14.06M Beat $13.23M Estimate
11 Sep 24